Lung Cancer Cytology and Small Biopsy Specimens: Diagnosis, Predictive Biomarker Testing, Acquisition, Triage & Management

Abstract In the 21st century, there has been a dramatic shift in the management of advanced stage lung carcinoma, and this has coincided with an increasing use of minimally invasive tissue acquisition methods. Both have had significant downstream effects on cytology and small biopsy specimens. Current treatments require morphological, immunohistochemical and/or genotypical subtyping of non-small cell lung carcinoma. To meet these objectives, standardized classification of cytology and small specimen diagnoses, immunohistochemical algorithms and predictive biomarker testing guidelines have been developed. This review provides an overview of current classification, biomarker testing, methods of small specimen acquisition and triage, clinical management strategies, and emerging technologies.